The oncolytic measles virus (MV-NIS), which uses the surface receptor CD46 for entry into cells is being trialled to treat drug resistant ovarian cancer in which CD46 is overexpressed [267,268]. The gene discussed is CD46; the disease is ovarian carcinoma.